Search
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT … [A275238, L54728] It is a fast-acting drug with a short duration of action.
Defibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalDefibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. … It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
Mebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
International brands: OvexProducts: Pantelmin 100 mg - Tabletten, QUEMOX TABLET 500 MGCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways … [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015]
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationaltools that can target the problematic overactivity of this pathway. … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Products: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mgAnifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigational[A237054] The design of the clinical trials use different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids … [A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism.
Products: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADETSomatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnThe actions of somatostatin are mediated via signalling pathways of G protein-coupled somatostatin receptors. … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as
Products: STILAMIN 3000 FOR INJECTION 3 mg/ampoule, SOMATOSAN 3 MG IV INFUZYON ICIN 1 AMPULTalazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigational[L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] … Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.
Products: HUMIRA 40 MG, HUMIRA 40 MG FSCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Categories: Drugs for Treatment of TuberculosisProducts: CICLOSERINA 250 MG CAPSULAS, SIKLOCAP 250 MG KAPSUL, 500 ADET